GlassScriptPhysician profile
Julie Pham
NPI 1962286286
$2,979.60
in general payments reported to CMS, 2019-2025
17 companies · $469 in 2025
The $469 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $182 · 2024: $2,328 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $900.42 | 2023-2025 | |
| Amgen INC. | $479.63 | 2024 | Enbrel, Otezla, Evenity |
| Glaxosmithkline, LLC. | $439.25 | 2024-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $194.25 | 2024 | |
| Ucb, INC. | $170.14 | 2024 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $161.66 | 2024 | Tremfya, Simponi Aria |
| Aurinia Pharma U.S., INC. | $124.70 | 2024 | Lupkynis |
| Gilead Sciences, INC. | $121.83 | 2024 | Vemlidy |
| Fresenius Kabi USA, LLC | $85.01 | 2024 | |
| Lilly USA, LLC | $79.63 | 2024 | Taltz, Zepbound |
| Alexion Pharmaceuticals, INC. | $70.65 | 2023-2024 | Strensiq |
| Organon LLC | $33.72 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $28.48 | 2024 | Opsumit, Uptravi |
| Sandoz INC. | $27.36 | 2024 | Hyrimoz |
| Biocon Biologics INC | $26.27 | 2024 | Hulio |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.19 | 2024 | Saphnelo |
| Alvogen INC | $14.41 | 2024 | Teriparatide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.